



INDICATION

Moderate to severe ulcerative colitis or Crohn's disease

PRIOR TO INITIATION

- ✓ Baseline FBC, renal function, LFT, and lipid profile
- ✓ Pre-immunosuppression screen as per BSG guidelines
- ✓ Up to date vaccinations, including shingles, as per BSG guidelines
- ✓ Recommend contraception to females of child bearing age (ideally avoiding oestrogen during higher dose induction phase)

DURING TREATMENT

- ✓ Monitor treatment response
- ✓ Consider extended induction if sub-optimal response
- ✓ Use the lowest JAK inhibitor dose to maintain remission
- ✓ Monitor FBC and LFT post-induction and 3-monthly thereafter
- ✓ Monitor post-induction lipid profile and refer if abnormal
- ✓ Monitor for infection - pause JAK inhibitor and restart once infection cleared

WHEN TO AVOID

- ✗ Active infection
- ✗ >65 years of age*
- ✗ Cancer or MACE risk factors*
- ✗ Active smoker or significant smoking history*
- ✗ VTE risk factors – use with caution
- ✗ Pregnancy or breastfeeding
- ✗ Females wishing to conceive
- ✗ Advanced liver disease (Child-Pugh C)
- ✗ Alongside drugs inhibiting or inducing CYP3A4 (relevant for tofacitinib + upadacitinib)

*no alternative treatments exist